All In Biotech

Drug Trial Radar · NCT00927797

Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)

Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas

Last checked: Nov 19, 2026Latest source record: Jun 25, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

185

Planned (sponsor's estimate)

Start

Feb 2005

Primary completion

Jan 2009

Study completion Jan 2012

Sponsor

Lead sponsor
Heidelberg UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Diakonie Krankenhaus Schwäbisch Hall, Germany; Klinikum der Universitaet Muenchen, Grosshadern; Klinikum am Plattenwald, Bad Friedrichshall, Germany; Diakonie-Klinikum Stuttgart; Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany; Universitätsmedizin Mannheim
First posted
Jun 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The combination of Fludarabine and Cyclophosphamide have yielded overall response rates of over 80% in previously untreated patients with indolent Non-Hodgkin-Lymphoma. However, hematotoxicity rates were high with Grade 3 and 4 toxicities of over 50%. Several studies have indicated that the treatment with Pentostatin and Cyclophosphamide causes lower hematotoxicity rates than the combination of Fludarabine and Cyclophosphamide. To evaluate the efficacy and safety of treatment with Pentostatin/Cyclophosphamide immuno-chemotherapy for patients with newly diagnosed or relapsed Immunocytoma/Morbus Waldenström, B-cell chronic lymphocytic leukemia (B-CLL) and other indolent CD20-positive B-NHL, an open, non-randomized, multi-center prospective phase II-study to evaluate the efficacy and safety of treatment with immuno-chemotherapy is conducted. Treatment consists of 6 courses of Pentostatin (4mg/m² on day 1), Cyclophosphamide (600mg/m² on day 1) and Rituximab (375mg/m² on day 0) administered every three weeks. Patients achieving complete or partial remission undergo maintenance therapy consisting of 8 courses of Rituximab (375mg/m²) administered every three months over a period of 2 years.

Conditions

  • Immunocytoma/Morbus Waldenström
  • B-Cell Non-Hodgkin's Lymphoma
  • B-Cell Chronic Lymphocytic Leukemia

Interventions

  • Cyclophosphamide, Pentostatin, RituximabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: overall response rateTime frame: after 6 months and after 36 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.